Radiopharm Theranostics Limited

Radiopharm Theranostics Limited is a clinical-stage biotechnology company specializing in the development of innovative radiopharmaceutical products for both diagnostic and therapeutic applications in oncology. Established in 2021 and headquartered in Australia, its primary focus is on advancing targeted radiopharmaceuticals that address significant unmet needs in cancer care. The company distinguishes itself by deliberately developing radiopharmaceutical agents for novel oncology targets, avoiding more conventional and widely explored markers such as PSMA, FAP, or SSTR2. Radiopharm Theranostics’ pipeline includes candidates aimed at non-small cell lung cancer, breast cancer, pancreatic ductal adenocarcinoma, advanced prostate cancer, brain metastases, and other solid tumors. Leveraging technologies such as nanobodies, antibodies, small molecules, and peptides, the company strives to deliver precision medicines designed for earlier detection and more personalized treatment of cancer. Notably, it has entered into strategic collaborations, such as with Lantheus Holdings, to further advance its clinical programs. Through its clinical pipeline and strategic partnerships, Radiopharm Theranostics Limited plays a pioneering role in shaping the future of oncology diagnostics and therapeutics within the biotechnology and health care sectors.